Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

  Email address:

BeyondSpring Starts China-US Phase III Trial of Lung Cancer Drug

publication date: Jun 29, 2016
BeyondSpring Pharma, a virtual New York city biopharma, has launched a China-US Phase III clinical trial of its lead drug, plinabulin. Plinabulin is a small-molecule infused drug that will be tested as an adjunct to docetaxel in patients with non-small cell lung cancer. According to BeyondSpring, plinabulin has dual anti-angiogenesis and immunotherapy mechanisms. The trial will enroll 550 patients: 440 in China and the rest in the US and Australia. Overall survival will be the primary endpoint. More details....

Share this with colleagues:  

This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes

Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China